- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Azad on the Design of the ARCHES Trial in mHSPC
Arun Azad, PhD, discusses the design of the phase 3ARCHES trial in metastatic hormone-sensitive prostate cancer.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Arun Azad, PhD, an associate professor at Peter MacCallum Cancer Centre and the University of Melbourne; fellow at Victorian Cancer Agency; and chair of the ANZUP Cancer Trials Group Translational, discusses the design of the phase 3ARCHES trial in metastatic hormone-sensitive prostate cancer (mHSPC).
The ARCHES study randomized patients with mHSPC to receive androgen deprivation therapy with enzalutamide (Xtandi) or placebo.
The trial was designed to evaluate all men with mHSPC rather than evaluating 1 specific subtype, says Azad.
Notably, the study included men with low- and high-volume mHSPC, men with newly diagnosed and relapsed/refractory mHSPC, and men who previously received docetaxel.
Additionally, ARCHES was a multicenter, international study; thus, the data are widely applicable, Azad concludes.
Related Content:
